Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Peripheral Nervous System Diseases × enfortumab vedotin × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 6 Urinary Bladder Neoplasms 3 Urethral Neoplasms 1 Ureteral Neoplasms 1 Peripheral Nervous System Diseases 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms 1 Metastatic Urothelial Cancer and Other Malignant Solid Tumors 1 Carcinoma in Situ 1

Interventions

pembrolizumab 1 enfortumab vedotin 1 Glutamine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07484022 2026-03-19

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Generate Biomedicines

Phase 1 Not yet recruiting

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡